Seeking Alpha

GlaxoSmithKline and Innoviva look for new Trelegy use

|About: GlaxoSmithKline plc (GSK)|By:, SA News Editor

GlaxoSmithKline (NYSE:GSK) and Innoviva (NASDAQ:INVA) announce the filing of a supplemental new drug application to the FDA for an additional indication for the use of Trelegy Ellipta for asthma in adults.

The companies note Trelegy Ellipta was approved in the U.S. in 2017 for the treatment of patients with chronic obstructive pulmonary disease.

Source: Press Release

Subscribe for full text news in your inbox